The Biomarkers Consortium, a public-private alliance that includes the U.S. Food and Drug Administration, the National Institutes of Health and major pharmaceutical companies, announced the start of the I-SPY 2 trial at a news conference this morning at NIH headquarters in Bethesda, Md. The project is led by the Foundation for the National Institutes of Health. M. D. Anderson will be one of the first of 20 national clinical trial sites to open. The trial combines personalized medicine with an innovative adaptive randomization approach designed to match each womans tumor with the drug most likely to control her disease.
Questions about Breast Cancer Trial Tests Multiple Drugs Quickly
Want more info about Breast Cancer Trial Tests Multiple Drugs Quickly?
Get free advice from education experts and Noodle community members.